Tuberculosis: Brief overview and its shifting paradigm for management in India

International Journal of Pharmacology

Volumn 6, Issue 6, 2010, Pages 755-783

  Imam, F ^a   Anwer, M K ^b   Iqbal, M ^c   Alam, S ^d   Khayyam, K U ^e   Sharma, M ^a  

^a HAMDARD UNIVERSITY   (India)

^b PRINCE SATTAM BIN ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^c KING SAUD UNIVERSITY   (Saudi Arabia)

^d INTEGRAL UNIVERSITY   (India)

^e Lala Ram Sarup Institute of TB and Respiratory Diseases   (India)

Author keywords

Diagnosis; Management; Short course chemotherapy; Symptoms; Tuberculosis

Indexed keywords

ALCOHOL; AMIKACIN; AMINOGLYCOSIDE; AMINOSALICYLIC ACID; AMPHOTERICIN B; ANTACID AGENT; BCG VACCINE; CALCIUM SALT; CISPLATIN; COTRIMOXAZOLE; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EDROPHONIUM; ETHAMBUTOL; FUROSEMIDE; GENTAMICIN; ISONIAZID; KANAMYCIN; NEOMYCIN; NEUROMUSCULAR BLOCKING AGENT; ORAL CONTRACEPTIVE AGENT; PHENYTOIN; PYRAZINAMIDE; PYRIDOXINE; RIFABUTIN; RIFAMPICIN; RIFAPENTINE; RIFATER; STREPTOMYCIN; THIOACETAZONE; TOBRAMYCIN; UNINDEXED DRUG; URATE;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; AGRANULOCYTOSIS; ANAPHYLACTIC SHOCK; ANAPHYLAXIS; ANEMIA; ANGIONEUROTIC EDEMA; ANOREXIA; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; APLASTIC ANEMIA; APNEA; ARTHRALGIA; ARTHRITIS; ARTICLE; ATAXIA; BACKACHE; BACTERIAL TRANSMISSION; BACTERIUM DETECTION; BLOOD DYSCRASIA; BLOOD TOXICITY; BRAIN TOXICITY; CHOLESTASIS; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COLOR DISCRIMINATION; CONFUSION; CONVULSION; DIARRHEA; DISEASE SEVERITY; DISORIENTATION; DIZZINESS; DROWSINESS; DRUG ABSORPTION; DRUG ALCOHOL INTERACTION; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG EXCRETION; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG INTOXICATION; DRUG MEGADOSE; DRUG METABOLISM; DRUG OVERDOSE; DRUG POTENTIATION; DRUG TISSUE LEVEL; DRUG WITHDRAWAL; DYSURIA; ENDOCARDITIS; EOSINOPHILIA; EPIGASTRIC PAIN; EUPHORIA; EXFOLIATIVE DERMATITIS; EXTRAPULMONARY TUBERCULOSIS; FATIGUE; FLU LIKE SYNDROME; FOOD; FOOD DRUG INTERACTION; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HEALTH CARE AVAILABILITY; HEALTH CARE POLICY; HEALTH PROGRAM; HEMATURIA; HEMOGLOBINURIA; HEMOLYSIS; HEMOLYTIC ANEMIA; HEPATITIS; HUMAN; HYPERSENSITIVITY REACTION; INCIDENCE; INDIA; JAUNDICE; KIDNEY FAILURE; LATENT TUBERCULOSIS; LEUKOPENIA; LIMB PAIN; LIVER DISEASE; LIVER FAILURE; LIVER INJURY; LIVER TOXICITY; LUNG INFECTION; LUNG INFILTRATE; LUNG TUBERCULOSIS; MALAISE; MEMORY DISORDER; MENTAL DISEASE; METHEMOGLOBINEMIA; MICROBIOLOGICAL EXAMINATION; MILIARY TUBERCULOSIS; MUSCLE WEAKNESS; MYCOBACTERIUM TUBERCULOSIS; NAUSEA; NAUSEA AND VOMITING; NEPHROTOXICITY; NEURITIS; NEUROMUSCULAR BLOCKING; NEUROMUSCULAR DISEASE; NEUROTOXICITY; NONHUMAN; OPTIC NERVE ATROPHY; OPTIC NERVE DISEASE; OPTIC NEURITIS; OTOTOXICITY; PARESTHESIA; PERIPHERAL NEUROPATHY; PHYSICAL EXAMINATION; PRURITUS; PSYCHOSIS; RASH; RECOMMENDED DRUG DOSE; SCOTOMA; SHORT COURSE THERAPY; SHOULDER HAND SYNDROME; SIDE EFFECT; SIDEROBLASTIC ANEMIA; SINGLE DRUG DOSE; SKIN DISEASE; SKIN MANIFESTATION; SKIN TINGLING; STEVENS JOHNSON SYNDROME; STOMACH IRRITATION; STOMATITIS; SYMPTOMATOLOGY; SYSTEMIC LUPUS ERYTHEMATOSUS; TERATOGENICITY; THORAX RADIOGRAPHY; THROMBOCYTOPENIA; TINNITUS; TREATMENT DURATION; TREND STUDY; TUBERCULIN TEST; TUBERCULOSIS; TUBERCULOSIS CONTROL; URINE RETENTION; VASCULITIS; VESTIBULOCOCHLEAR NERVE DISEASE; VISUAL ACUITY; VOMITING; XEROSTOMIA;

EID: 77957979441     PISSN: 18117775     EISSN: 18125700     Source Type: Journal    
DOI: 10.3923/ijp.2010.755.783     Document Type: Article

References (159)

1. Advisory Council for the Elimination of Tuberculosis, 1999. TB elimination revisited: Obstacles, opportunities and a renewed commitment. Morb. Mortal. Wkly. Rep., 48: 1-13.
2. Ahuja, S.S., S.K. Ahuja, K.R. Phelps, W. Thelmo and A.R. Hill, 1992. Hemodynamic confirmation of septic shock in disseminated tuberculosis. Crit. Care. Med., 20: 901-903.
3. Alvarez, S. and W.R. McCabe, 1984. Extrapulmonary tuberculosis revisited: A review of experience at Boston city and other hospitals. Medicine, 63: 25-55.
4. Alvarez, S., C. Shell and S.L. Berk, 1987. Pulmonary Tuberculosis in elderly men. Am. J. Med., 82: 602-606.
5. Anderson, D.G and M. Jewell, 1945. The absorption, excretion and toxicity of streptomycin in man. New. Engl. J. Med., 233: 485-491.
6. Aneja, K.S., 1952. Chemotherapy in national tuberculosis programme. NTI Newslett, 19: 58-70.
7. Antony, V.B., 2003. Immunological mechanisms in pleural disease. Eur. Respir. J., 21: 539-544.
8. Appel, G.B., 1982. Aminoglycoside Nephrotoxicity: Physiologic Studies of the Sites of Nephron Damage. In: The Aminoglycosides: Microbiology, Clinical Use and Toxicity, Whelton, A. and H.C. Neu, (Eds.). Marcel Dekker, New York, pp: 269-282.
9. Aqil, M., F. Imam, A. Hussain, M.S. Alam, P. Kapur and K.K. Pillai, 2006. A pharmacovigilance study for monitoring adverse drug reactions with antihypertensive agents at a South Delhi hospital. Int. J. Pham. Pract, 14: 311-313.
10. Aronoff, G.R., S.T. Pottratz and M.E. Brier, 1983. Aminoglycoside accumulation kinetics in rat renal parenchyma. Antimicrob. Agents Chemother., 23: 74-78.
11. Arora, V.K. and R.S. Bedi, 1989. Geriatric tuberculosis in himachal pradesh- a clinico radiological profile. JAPI, 37: 205-206.
12. Avery, G.S., 1980. Drug Treatment: Principles and Practice of Clinical Pharmacology and Therapeutics. 2nd Edn., Adis Press, Churchill Livingstone.
13. BCG Conference, 1962. Proceedings of the VI all India BCG conference. Bangalore, pp: 20-30.
14. Baciewicz, A.M., D.R. Sokos and R.I. Cowan, 2003. Aminoglycoside-associated nephrotoxicity in the elderly. Ann. Pharmacother., 37: 182-186.
15. Bailey, W.C., H. Weill, T.A. De Rouen, M.M. Ziskind and H.A. Jackson, 1974. The effect of isoniazid on transaminase levels. Ann. Intern. Med., 81: 200-202.
16. Bailey, M.C. and P.C. Wmdle-Taylor, 1981. Tuberculous laryngitis: A series of 37 patients. Laryngocope, 91: 93-100.
17. Balasubramaniam, V.N., K. Oommen and R. Samuel, 2000. DOT or not? Direct observation of anti-TN treatment and patient outcomes, Kerala State, India. Int. J. Tuberc. Lung. Dis., 4: 409-413.
18. Bass, J.B., L.S. Jr. Farer, P.C. Hopewell, R. O'Brien and R.F. Jacobs et al., 1994. Treatment of tuberculosis and tuberculosis infections in adults and children. American thoracic society and the centers for disease control and prevention. Am. J. Respir. Crit. Care Med., 149: 1359-1374.
19. Bates, D.E., 2003. Aminoglycoside ototoxicity. Drugs Today, 39: 277-285.
20. Battaglia, A., K. Pak, D. Brors, D. Bodmer, J.A. Frangos and A.F. Ryan, 2003. Involvement of ras activation in toxic hair cell damage of the mammalian cochlea. Neuroscience, 122: 1025-1035.
21. Baylis, C, H.R. Rennke and B.M. Brenner, 1977. Mechanisms of the defect in glomerular ultrafiltration associated with gentamicin administration. Kidney Int., 12: 344-353.
22. Behr, M.A., S.A. Warren, H. Salamon, P.C. Hopewell and P.A. de Leon et al, 1999. Transmission of Mycobacterium tuberculosis from patients smear negative for acid fast bacilli. Lancet, 353: 444-449.
23. Belanger, A.E., G.S. Besra, M.E. Ford, K. Mikusova, J.T. Belisle, P. J. Brennan and J.M. Inamme, 1996. The embAB genes of Mycobacterium avium encode an arabinosyl transferase involved in cell wall arabinan biosynthesis that is a target for the antimycobacterial drug ethambutol. Proc. Natl. Acad. Sci. USA, 93: 11919-11924.
24. Benjamin, P.V., 1973. Dr PV Benjamin no more. Indian J. Tuberc, 20: 33-34.
25. Bennett, W.M., W.C. Elliott, D.C. Houghton, D.N. Gilbert, J. DeFehr and D.A. McCarron, 1982. Reduction of experimental gentamicin nephrotoxicity in rats by dietary calcium loading. Antimicrob. Agents Chemother., 22: 508-512.
26. Bhore, S., 1946. Ministry of health: Report on the health survey and development committee. Ministry of Health, Government of India, New Delhi, pp: 157-167.
27. Blanchard, J.S., 1996. Molecular mechanisms of drug resistance in Mycobacterium tuberculosis. Annu. Rev. Biochem., 65: 215-239.
28. Brown, W.G.S., J. Ballantyne and J. Groves, 1965. Diseases of the Ear, Nose and Throat. 2nd Edn, Butterworth and Co. Ltd., London, pp: 539.
29. Brummett, R.E., 1983. Animal models of aminoglycoside antibiotic ototoxicity. Rev. Infect. Dis., 5: 294-303.
30. Budavari, S., 1989. The Merck Index: An Encyclopedia of Chemicals, Drugs and Biologicals. 11th Edn., Merck and Co. Inc., New Jersey.
31. Byrd, R.B., B.R. Horn, D.A. Solomon and G.W. Griggs, 1979. Toxic effects of isoniazid in tuberculosis chemoprophylaxis. Role of biochemical monitoring in 1,000 patients. JAMA., 241: 1239-1241.
32. Cauthen, G.M, J.O. Kilburn, G.D. Kelly and R.C. Good, 1988. Resistance to anti-tuberculosis drugs in patients with and without prior treatment: survey of 31 state and large city laboratories, 1982-1986. Am. Rev. Respir. Dis., 137: 260-260.
33. Cavalcanti, Z.D.R., M.D. Alberquerque and A. Camplo, 2006. Characteristics of elderly tuberculosis pts in Recife Brazila, a contribution to the tuberculosis control program. J. Bras. Pneumol., 32: 535-543.
34. Chaudhuri, K., P. Jagota and N. Parimala, 1993. Results of treatment with a short course chemotherapy regimen used under field conditions in district tuberculosis programme. Ind. J. Tub., 40: 83-89.
35. Chow, A.W. and P.J. Jewesson, 1985. Pharmacokinetics and safety of antimicrobial agents during pregnancy. Rev. Infect. Dis., 7: 287-313.
36. Chung, C.L., C.H. Chen, J.R. Sheu, Y.C. Chen and S.C. Chang, 2005. Proinflammatory cytokines, transforming growth factorbl and fibrinolytic enzymes in loculated and free-flowing pleural exudates. Chest 128: 690-697.
37. De La Iglesia, A.I. and H.R. Morbidoni, 2006. Mechanisms of action of and resistance to rifampicin and isoniazid in Mycobacterium tuberculosis: New information on old friends. Rev. Argent. Microbiol, 38: 97-109.
38. De-Jager, P. and R. Van-Altena, 2002. Hearing loss and nephrotoxicity in long-term aminoglycoside treatment in patients with tuberculosis. Int. J. Tuberc. Lung Dis., 6: 622-627.
39. Dijk, J.M.V. and A.J. Rosin, 1993. A comparison of clinical features of mycobacterial infections in young and elderly Patients. Neth. J. Med., 42: 12-15.
40. Dollery, C, 1991. Therapeutic Drugs by Collin Dollery. 2nd Edn., Churchill Livingston, London, pp: 100-103.
41. Elias, W.F. and J. Durso, 1945. Blood, urine and faecal levels of streptomycin in the treatment of human infections oiE. Typhosa. Science, 101: 589-591.
42. Ellenhorn, M.J. and D.G. Barceloux, 1988. Medical Toxicology-Diagnosis and Treatment of Human Poisoning. Elsevier Science Publishing Co., Inc., New York.
43. Fair, B.F., 2000. Rifamycins. In: Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases, Mandell, G.L., J.E. Bennett and R. Dolin (Eds.). 5thEdn., Churchill Livingstone, Philadelphia, pp: 348-361.
44. Fong, I.W., R.S. Fenton and R. Bird, 1981. Comparative toxicity of gentamicin versus tobramycin: A randomized, prospective study. J. Antimicrob. Chemother., 7: 81-88.
45. Fox, H.H., 1952. Synthetic tuberculostats. I. Pyridine carboxylic acid derivatives. J. Org. Chem., 17: 542-546.
46. Fox, W., 1962. Self-administration of medicaments: A review of published work and a study of the problems. Bull. Int. Union Tuberc, 3: 307-331.
47. Fox, W., 1981. Whither short course chemotherapy. Br. J. Dis. Chest 75: 331-357.
48. Frimodt Moller, J., P. Benjamin and P. Mathew, 1952. Results of mass X-ray surveys in village population at Madanapalle. Proceedings of the 9th Tuberculosis Workers Conference, (TWC'52), Lucknow, pp: 133-149.
49. Furesz, S., 1970. Chemical and biological properties of rifampicin. Antibiot. Chemother., 16: 316-351.
50. GDF., 2005. Stop TB partnership. Achievement Reports.
51. Gangadharam, P.R., 1986. Isoniazid, rifampin and hepatotoxicity. Am. Rev. Respir. Dis., 133: 963-965.
52. Garibaldi, R.A., RE. Drusin, S.H. Ferebee and M.B. Gregg, 1972. Isoniazid-associated hepatitis. Report of an outbreak. Am. Rev. Respir. Dis., 106: 357-365.
53. Gholami, K., E. Kamali, M. Hajiabdolbaghi and G. Shalviri, 2006. Evaluation of anti-tuberculosis induced adverse reactions in hospitalized patients. Pharm. Prac.,4: 134-138.
54. Gilman, A.G., T.W. Rail, A.S. Nies and P. Tayer, 1990. Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th Edn., Pergamon Press, New York, pp: 1317-1322, 1463-1495.
55. Gothi, G.D., A.K. Chakraborty and G.C. Banerjee, 1974. Interpretation of photofluorograms of active pulmonary TB patients found in epidemiological survey and their five year fate. Ind. J. Tub., 21: 90-97.
56. Graber, C.D., J. Jebaily, R.L. Galphin and E. Doering, 1973. Light chain proteinuria and humoral immunocompetence in tuberculous patients treated with rifampin. Am. Rev. Respir. Dis., 107: 713-717.
57. Grosset, J. and S. Leventis, 1983. Adverse effects of rifampin. Rev. Infect. Dis., 5: 440-446.
58. Gumbo, T., A. Louie, W. Liu, D. Brown, P.G. Ambrose, S.M. Bhavnani and G.L. Drusano, 2007. Isoniazid Bactericidal activity and resistance emergence: Integratingpharmacodynamics and pharmacogenomics to predict efficacy in different ethenic populations. Antimicrob. Agents. Chemother., 51: 2329-2336.
59. Haddad, L. and J. Winchester, 1983. Clinical Management of Poisoning and Drug Overdose. WB Saunders Co., USA.
60. Hall, R.G., R.D. Leff and T. Gumbo, 2009. Treatment of active pulmonary tuberculosis in adults: Current standards and recent advances. Insights from the society of infectious diseases pharmacists. Pharmacotherapy, 29: 1468-1481.
61. Holdiness, M.R., 1985. Cerebrospinal fluid pharmacokinetics of antituberculosis drugs. Clin. Pharmacokinet., 10: 532-534.
62. Huber, W.G., 1966. Streptomycin. In: Veterinary Pharmacology and Therapeutics, Jones, L.M. (Ed.). 3rd Edn., Iowa State College Press, Iowa, pp: 519-530.
63. Humes, H.D., M. Sastrasinh and J.M. Weinberg, 1984. Calcium is a competitive inhibitor of gentamicin-renal membrane binding interactions and dietary calcium supplementation protects against gentamicin nephrotoxicity. J. Clin. Invest, 73: 134-147.
64. ICMR, 1976. Review of the national tuberculosis programme. Report of the Expert Committee, New Delhi.
65. ICORCI, 1988. In depth study of national tuberculosis programme of India. Bangalore.
66. ICMR, 1959. Tuberculosis in India; A National Sample Survey 1955-1958. ICMR, New Delhi, pp: 1-12.
67. Iseman, M.D., 1993. Treatment of multidrug-resistant tuberculosis. N. Engl. J. Med., 329: 784-791.
68. Iseman, M.D., 2000. How is Tuberculosis Transmitted? In A Clinician's Guide to Tuberculosis. Williams & Wilkins, Philadelphia, pp: 51-62.
69. Jacobs, Jr. W.R., 2000. Mycobacterium Tuberculosis: A Once Genetically Intractable Organism. In: Molecular Genetics of Mycobacteria, Hatfall, G.F. and W.R.Jr. Jacobs (Eds.). ASM Press, Washington, D.C.
70. Jayaram, R., R.K. Shandil, S. Goenkar, P. Kaur and B.L. Suresh et al, 2004. Isoniazid Phrmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosis. Antimicrob. Agents Chemother., 48: 2951-2957.
71. Karnik, A.M., M. A. Al-Shamali and F.F. Fenech, 1985. A case of ocular toxicity to efhambutol-an idiosyncratic reaction?. Postgrad. Med. J., 61: 811-813.
72. Keating, M.J., G.P. Bodey, M. Valdivieso and V. Rodriguez, 1979. A randomized comparative trial of three aminoglycosides-comparison of continuous infusions of gentamicin, amikacin and sisomicin combined with carbenicillin in the treatment of infections in neutropenic patients with malignancies. Medicine, 58: 159-170.
73. Keers, R.Y., 1978. Pulmonary Tuberculosis: A Journey Down the Centuries. WB Saunders Co., London.
74. Keys, T.F., S.B. Kurtz, J.D. Jones and S.M. Muller, 1981. Renal toxicity during therapy with gentamicin or tobramycin. Mayo Clin. Proa, 56: 556-559.
75. Khatri, G.R. and T.R. Fneden, 2000. The status and prospects of tuberculosis control in India. Int. J. Tuberc. Lung Dis., 4: 193-200.
76. Khayyam, U.K., F. Imam, M. Sharma, K.K. Pillai and D. Behera, 2010. Pyrazinamide-induced maculopapular rash: The commonly used first-line antitubercular drug. Indian J. Dermatol.,
77. Koch, R., 1938. Die aetiologie und die bekampfung der tuberkulose. Med. Classics, 2: 853-880.
78. Kochi, A., 1991. The global tuberculosis situation and the new control strategy of the world health organization. Tubercle, 72: 1-6.
79. Kumar, P., 2005. Journey of tuberculosis control movement in india: National tuberculosis programme to revised national tuberculosis control programme. Ind. J. Tuberc, 52: 63-71.
80. Lee, B.H., W.J. Koh, M.S. Choi, G.Y. Suh, M.P. Chung, H. Kim and O.J. Kwon, 2005. Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy. Chest, 127: 1304-1311.
81. Li, B., Z. Wang, J.J. Fang, C.Y. Xu and W.X. Chen, 2007. Evaluation of prognostic markers in severe drug-induced liver disease. World J. Gastroenterol., 13: 628-632.
82. Lietman, P.S. and C.R. Smith, 1983. Aminoglycoside nephrotoxicity in humans. J. Infect. Dis., 5: 284-292.
83. Light, R.W., 2001. Tuberculous Pleural Effusions. In: Pleural Diseases, Light, R.W. (Ed). 4th Edn., Williams and Wilkms, Philadelphia, pp: 182-195.
84. Luft, F.C. and A.P. Evan, 1980. Comparative effects of tobramycin and gentamicin on glomerular ultrastructure. J. Infect. Dis., 142: 910-914.
85. Mandell, G.L. and M.A. Sande, 1985. Antimicrobial Agents: Penicillins, Cephalosporins and Other Beta-Lactam Antibiotics. In: Goodman and Gilman's the Pharmaceutical Basis of Therapeutics, Gilman, A.G., L.S. Goodman, T.W. Rail and F. Murad (Eds.). 7th Edn., Macmillan Publishing Co., New York, pp: 1115-1149.
86. Marshall, E.K., 1948. The absorption, distribution and excretion of streptomycin. J. Pharmacol. Exp. Therapeut, 92: 43-48.
87. Marynowski, A. and E. Sianozecka, 1972. Comparison of the incidence of congenital malformations in neonates from healthy mothers and from patients treated for tuberculosis. Ginekol. Pol., 43: 713-715.
88. McGlynn, K.A., E.D. Lustabader, R.G. Sharrar, E.C. Murphy and W.T. London, 1986. Isoniazid prophylaxis in hepatitis B carriers. Am. Rev. Respir. Dis., 134: 666-668.
89. Meisel, P., 2002. ArylamineN-acetyltransferases and drug response. Pharmacogenomics, 3: 349-366.
90. Merck Index, 1989. The Merck Index an Encyclopedia of Chemicals Drugs and Biologicals. 11th Edn., Merck and Co., Inc., Rahway, New Jersey, USA.
91. Miller, R.R., J. Porter and D.J. Greenblatt, 1979. Clinical importance of the interaction of phenytoin and isoniazid: A report from the Boston collaborative drug surveillance profram. Chest, 75: 356-358.
92. Mitchell, C.J., S. Bullock and B.D. Ross, 1977. Renal handling of gentamicin and other antibiotics by the isolated perfused rat kidney: Mechanism of nephrotoxicity. J. Antimicrob. Chemother., 3: 593-600.
93. Mohan, A., S.K. Sharma and J.N. Pande, 1996. Acute respiratory distress syndrome (ARDS) in miliary tuberculosis: A twelve year experience. Ind. J. Chest. Dis. Allied. Sci.,38: 157-162.
94. Molavi, A., 1990. Antimicrobials III: Sulfonamides, Trimethoprim and Anti-Mycobacterial Agents. In: Basic Pharmacology in Medicine, Di Palma, J. and J. Di Gregono's (Eds.). 3rd Edn., McGraw-Hill Book, USA.
95. Moore, R.D., C.R. Smith and P.S. Lietman, 1984a. Risk factors for the development of auditory toxicity in patients receiving aminoglycosides. J. Infect. Dis., 149: 23-30.
96. Moore, R.D., C.R. Smith and J.J. Lipsky, E.D., Mellits and P. S., Lietman, 1984b. Risk factors for nephrotoxicity in patients with aminoglycosides. Ann. Internal Med., 100: 352-357.
97. Nagpaul, D.R., D.M. Savic, K.P. Rao and G.V. Baily, 1968. Case-finding by microscopy. Bull. Int. Union Tuberc, 61: 148-158.
98. Nardell, E.A. and W.F. Piessens, 2000. Transmission of Tuberculosis. In: Tuberculosis: A Comprehensive International Approach, Reichman, L.B. and E.S. Hershfield (Eds.). 2ndEdn., Marcel Dekker, New York,pp: 215-240.
99. National Tuberculosis Institute, 1993. Year Book onNTP in India. National Tuberculosis Institute, Bangalore.
100. Neu, H.C. and C.L. Bendush, 1976. Ototoxicity of tobramycin: A clinical overview. J. Infect. Dis., 134: 206-218.
101. Nyboe, J., 1968. Results of the international study on x-ray classification. Bull. Int. Union Tuberc, 41: 115-124.
102. Pablos-Mendez, A., M.C. Raviglione, A. Laszlo, N. Binkin and H.L. Rieder et al., 1998. Global surveillance for antituberculosis-drug resistance, 1994-1997. World health organization-international union against tuberculosis and lung disease working group on anti-tuberculosis drug resistance surveillance. N. Engl. J. Med., 338: 1641-1649.
103. Patel, V., F.C. Luft and M.N. Yum, 1975. Enzymuna in gentamicin-induced kidney damage. Antimicrob. Agents Chemother., 7: 364-369.
104. Peloquin, C.A., 2002. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs, 62: 2169-2183.
105. Perez-Guzman, C, M.H. Vargas, A.C. Torres and H.V. Villarreal, 1999. Does aging modify pulmonary tuberculosis: A meta-analytical review. Chest, 116: 961-967.
106. Pinet, G., 2001. Good Practice in Legislation and Regulations forTB Control: An Indicator of Political Will. World Health Organization, Geneva.
107. Piqueras, A.R., L. Marruecos, A. Artigas and C. Rodriguez, 1987. Miliary tuberculosis and adult respiratory distress syndrome. Intensive Care. Med., 13: 175-182.
108. Postlethwaite, A.E., A.G. Bartel and W.N. Kelley, 1972. Hyperuricemia due to ethambutol. N. Engl. J. Med., 286: 761-762.
109. Powell, S.H., W.L. Thompson and M.A. Luthe, R.C. Stern and D.A. Grossniklaus et al., 1983. Once-daily vs. continuous aminoglycoside dosing: Efficacy and toxicity in animal and clinical studies of gentamicin, netilmicin and tobramycin. J. Infect. Dis., 147: 918-932.
110. Pratt, W.B. and R. Fekaty, 1986. Bactericidal Inhibitors of Protein Synthesis, the Aminoglycosides. Oxford University Press, Oxford, pp: 153-183.
111. Puri, M.M., S. Kumar, B. Prakash, K. Lokender, A. Jaiswal and D. Behera, 2010. Tuberculosis pneumonia as a primary cause of respiratory failure-report of two cases. Ind. J. Tuberc, 57: 41-47.
112. +-ATPase activities in renal tissues of rats. Antimicrob. Agents Chemother., 24: 815-818.
113. Rao, K.P., S.S. Nair, N. Naganathan and R. Rajalakshmi, 1971. Assessment of diagnosis of pulmonary tuberculosis by sputum microscopy in a district tuberculosis programme. Ind. J. Tub., 18: 10-21.
114. Reynolds, J.E.F., 1982. Martindale, the Extra Pharmacopoeia. 28th Edn., Pharmaceutical Press, London, pp: 1569-1570.
115. Reynolds, J.E.F., 1989. Martindale: The Extra Pharmacopeia. 29th Edn., Pharmaceutical Press, London, ISBN: 0 7020 2617 4, pp: 1249.
116. Reynolds, J.E.F., 1993. Martindale, the Extra Pharmacopoeia. 30th Edn., Pharmaceutical Press, London, pp: 164-165.
117. ®, 2009. Product Monograph. Sanofi-Aventis Canada Inc., Quebec, Canada.
118. Ryan, F., 1992. Tuberculosis: The Greatest Story Never Told. SWIFT, Yorkshire.
119. Schaberg, T., K. Rebhan and H. Lode, 1996. Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. Eur. Respir. J., 9: 2026-2030.
120. Schentag, J.J., F.M. Gengo, M.E. Plaut, D. Danner, A. Mangione and W.J. Jusko, 1979. Urinary casts as an indicator of renal tubular damage in patients receiving aminoglycosides. Antimicrob. Agents Chemother., 16: 468-474.
121. Schippers, M.K., D.T. Scharte, A. letter, B. Scheidel and U. Fuhr et al, 2005. Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses. Antimicrob. Agents Chemother., 49: 1733-1738.
122. Sharma, S.K., A. Balamurugan and P.K. Saha, 2002. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antitubercular treatment. Am. J. Respir., 166: 907-908.
123. Sharma, H., M. Aqil, F. Imam, M.S. Alam, P. Kapur and K.K. Pillai, 2007. A pharmacovigilance study in the department of medicine of a university teaching hospital. Pharmacy Pract, 5: 46-49.
124. Sharma, M., U.K. Khayyam, V. Kumar, F. Imam, K.K. Pillai and D. Behera, 2008. Influence of honey on adverse drug reactions due to anti-tuberculosis drugs in pulmonary tuberculosis patients. Continental J. Pharmacol. Toxicol. Res., 2: 6-11.
125. Sharma, S.K., A. Mohan, A. Sharma and D.K. Mitra, 2005. Miliary tuberculosis: New insights into an old disease. Lancet Infect. Dis., 5: 415-430.
126. Sikand, B.K and S.P. Pamra, 1956. Domiciliary treatment-results of antibiotic therapy. Proceedings of the 13th TB Workers Conference, (TBWC'56), TB Association of India, Trivandrum, pp: 179-213.
127. Sikand, B.K., 1951. Some observations on the organised home treatment scheme in Delhi. Proceedings of 8fh TB Workers Conference, (TBWC'51), TB Association of India, New Delhi, pp: 90-102.
128. Singhal, K.C., J.K. Grover, R. Moideen and K. Verma, 1990. Incidences of adverse reactions to antitubercular drugs. Ind. J. Pharmac, 22: 231-238.
129. Smmk, F., B.V. Hoek, J. Ringers, R.V. Altena and S.M. Arend, 2006. Risk factors of acute hepatic failure during antituberculosis treatment: Two cases and literature review. Neth. J. Med., 64: 377-384.
130. Smith, C.R., J.J. Lipsky and O.L. Laskin, 1980. Double-blind comparison of the nephrotoxicity and auditory toxicity of gentamicin and tobramycin. New Engl. J. Med., 302: 1106-1109.
131. Snider, Jr. D.E., 1980. Pyridoxine supplementation during isoniazid therapy. Tubercle, 61: 191-196.
132. Sokoll, M.D. and S.D. Gergis, 1981. Antibiotics and neuromuscular function. Anesthesiology, 55: 148-159.
133. Stout, J.E., J.J. Engemann, A.C. Cheng, E.R. Fortenberry and CD. Hamilton, 2003. Safety of 2 months of rifampin and pyrazinamide for treatment of latent tuberculosis. Am. J. Respir. Crit. Care. Med., 167: 824-827.
134. Swan, S.K., 1997. Aminoglycoside nephrotoxicity. Semin. Nephrol, 17: 27-33.
135. Sydow, M., A. Schauer, T.A. Crozier and H. Burchardi, 1992. Multiple organ failure in generalized disseminated tuberculosis. Respir. Med., 86: 517-519.
136. Taki, R., M. Sugiura, T. Sonta, S. Chiba, N. Sayo, Y. Hiraki and M. Yoshizawa, 2008. A case of adrenal tuberculosis complicated with acute exacerbation of adrenal insufficiency during the initial phase of antituberculosis therapy for pulmonary tuberculosis. Kekkaku, 83: 87-91.
137. Telzak, E.E., B.A. Fazal, C.L. Pollard, G.S. Turett, J.E. Justman and S. Blum, 1997. Factors influencing time to sputum conversion among patients with smear-positive pulmonary tuberculosis. Clin. Infect. Dis., 25: 666-670.
138. Tuberculosis Association of India, New Delhi, 1939. Proceedings of tuberculosis association of India. New Delhi, pp: 171-182.
139. TCC, 1964. A concurrent comparison of intermittent (twice-weekly) Isoniazid plus streptomycin and daily isoniazid plus PAS in the domiciliary treatment of pulmonary tuberculosis. Bull. World Health Organ., 31: 247-271.
140. Van Scoy, R. and C. Wilkowske, 1987. Antituberculosis agents. Mayo Clin. Proa, 62: 1129-1136.
141. Verma, S.K., S. Kant S. Kumar and R. Prasad, 2008. A five-year follow-up study of revised national tuberculosis control programme of India at Lucknow. Ind. J. Chest Dis. Allied Sci., 50: 195-197.
142. Vernon, A.A., 2004. Rifamycin Antibiotics, with a Focus on Newer Agents. In: Tuberculosis, Rom, W.N. and S.M. Gray (Eds.). 2nd Edn., Williams & Wilkms, Philadelphia, pp: 759-771.
143. Vilcheze, C, H.R Morbidoni, T.R Weisbrod, H. Iwamoto, M. Kuo, J.C. Sacchettim and W.R Jr. Jacobs, 2000. Inactivation of the inhA-encoded fatty acid synthase II (FASH) enoyl-acyl carrier protein reductase induces accumulation of the FASI end products and cell lysis of Mycobacterium smegmatis. J. Bacteriol., 182: 4059-4067.
144. WHO., 1992. Tuberculosis Programme Review-India. World Health Organization, Geneva.
145. WHO, 1994. Frame Work for Effective Tuberculosis Control. World Health Organisation, Geneva.
146. WHO, 1998. WHO Global Tuberculosis Programme: Global TB Control. World Health Organization, Geneva.
147. WHO, 2004. The Health Academy Avoiding Tuberculosis Self Study Programme on Tuberculosis. World Health Organization, Geneva, pp: 5-16.
148. WHO, 2008. Global tuberculosis control: Surveillance, planning, financing: WHO reports 2008. World Health Organization, Geneva, (WHO/ HTM7TB/ 2008.393.
149. WHO, 2009a. Treatment of Tuberculosis: Guidelines for National Programmes. 4th Edn., World Health Organization, Geneva.
150. WHO, 2009b. Global tuberculosis control-epidemiology, strategy, financing. World Health Organization, Report 2009. http://www.who.int/tb/publications/ global_r eport/2009/en/index. html.
151. Warrington, R.J., G.R. Hogg, F. Paraskevas and K.S. Tse, 1977. Insidious rifampin-associated renal failure with light-chain proteinuria. Arch. Intern. Med., 137: 927-930.
152. Wilson, W.R., C.J. Wilkowske, A.J. Wright, M.A. Sande, and J.E. Geraci, 1984. Treatment of streptomycin-susceptible and streptomycin-resistant enterococcal endocarditis. Ann. Internal Med., 100: 816-823.
153. Windholz, M., S. Budavari, L.Y. Stroumtsos, and M.N. Fertig, 1983. The Merck Index, an Encyclopedia of Chemicals and Drugs. 10th Edn., Merck and Co. Inc., New Jersey, USA., ISBN: 0911910271.
154. Wobeser, W., L. Yuan and M. Naus, 1999. The tuberculosis treatment completion study group. Outcome of pulmonary tuberculosis treatment in the tertiary care setting Toronto. Can. Med. Assoc. J., 160: 789-794.
155. Wong, P.C., W.W. Yew, C.F. Wong, and H.Y. Choi, 1995. Ethambutol-induced pulmonary infiltrates with eosinophilia and skin involvement. Eur. Respir. J., 8: 866-868.
156. Wood, C.A., S.J. Kohlhepp, P.W. Kohnen, D.C. Houghton and D.N. Gilbert, 1986. Vancomycin enhancement of experimental tobramycin nephrotoxicity. Antimicrob. Agents Chemother., 30: 20-24.
157. Yee, D., C. Valiquette and M. Pelletier, 2003. Incidence of serious side effects from first-line antituberculsis drugs among patients treaed for active tuberculosis. Am. J. Respir., 167: 1472-1477.
158. Zhang, Y., 2004. Isoniazid. In: Tuberculosis, Rom, W.N. and S.M. Gray (Eds.). 2nd Edn., Williams and Wilkins, Philadelphia, pp: 739-758.
159. Zimhony, O., J.S. Cox, J.T. Welch, C. Vilcheze and W.R. Jacobs Jr., 2000. Pyrazinamide inhibits the eukaryotic like fatty acid synthase I (FASI) of the Mycobacterium tuberculosis. Nat. Med., 6: 1043-1047.